Titlebook: Lung Cancer; Treatment and Resear Karen L. Reckamp Book 2016 Springer International Publishing Switzerland 2016 Genomics.Lung cancer.Lung n

Panacea

Chemotherapy for Advanced Non-small Cell Lung Cancer,cular drivers and the role of the immune system in cancer therapy have brought new drugs to the armamentarium. Despite these advances, cytotoxic chemotherapy remains a substantial part of therapy for most patients in locally advanced and metastatic stage. Initially thought to be a chemotherapy-resis

DIS

Multimodality Therapy for NSCLC, Although the concurrent use of both treatment modalities has been shown to be superior to sequential therapy, the role for additional chemotherapy, either as induction or as consolidation, remains unclear. Targeted therapy has met limited success in the treatment of unselected patients with stage I

放肆的你

Parley

Immunotherapy in Lung Cancer,vital to malignant progression. Immunotherapies act by enhancing the patient’s innate immune response and hold promise for inducing long-term responses in select patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Immune checkpoint inhibitors, in particular, inhibitor

功多汁水

Palliative Care in Lung Cancer, with advanced lung cancer is very high and has a negative impact on their quality of life (QOL). Palliative care with its focus on the management of symptoms and addressing physical, psychosocial, spiritual, and existential suffering, as well as medically appropriate goal setting and open communica

托運(yùn)

Management of Lung Cancer in the Elderly,e-half of patients with lung cancer fall into the elderly subgroup. There is dearth of high level of evidence regarding the management of lung cancer in the elderly in the three broad stages of the disease including early-stage, locally advanced, and metastatic disease. A major reason for the lack o

enlist

Cleave

Small Cell Lung Cancer,y present with a short duration of symptoms and frequently (60–65?%) with metastatic disease. SCLC is a heterogeneous disease including extremely chemosensitive and chemoresistant clones. For this reason, a high percentage of patients respond to first-line chemotherapy but rapidly succumb to the dis

corpus-callosum

地牢